Ávila-Villanueva Marina, Dolado Alberto Marcos, Fernández-Blázquez Miguel
Research in Alzheimer's Disease, Departamento de Psicología Experimental, Procesos Cognitivos y Logopedia Universidad Complutense de Madrid, Madrid, Spain.
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.
J Alzheimers Dis Rep. 2023 Jun 1;7(1):505-512. doi: 10.3233/ADR220100. eCollection 2023.
The development of Alzheimer's disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before the onset of MCI. Indeed, an early risk factor could promote the appearance of additional ones through a continuum. The presence of various risk factors may trigger specific biomarkers. In this review, we comment on how modifiable risk factors for AD may be reverted, thus correlating with a possible decrease in the specific biomarkers for the disease. Finally, we discuss the development of a suitable AD prevention strategy by targeting modifiable risk factors, thereby increasing the level of "precision medicine" in healthcare systems worldwide.
阿尔茨海默病(AD)的发展经历三个连续阶段:即临床前期、前驱期或轻度认知障碍(MCI)以及痴呆期。此外,临床前期阶段可根据生物标志物的存在情况分为不同亚阶段,这些生物标志物在MCI发作前的不同时间点出现。事实上,早期风险因素可能通过一个连续过程促使其他风险因素出现。各种风险因素的存在可能触发特定的生物标志物。在本综述中,我们阐述了AD的可改变风险因素如何得以逆转,进而与该疾病特定生物标志物的可能减少相关联。最后,我们讨论通过针对可改变风险因素制定合适的AD预防策略,从而提高全球医疗保健系统中“精准医学”水平的问题。